Association of ORMDL3 and IKZF3 expression with the IL2RA rs2104286 risk variant in relapsing-remitting multiple sclerosis

Authors

  • Milan Stefanović VINČA Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Department for Radiobiology and Molecular Genetics, Mike Petrovića Alasa 12-14, 11351 Belgrade, Serbia https://orcid.org/0000-0003-4272-2370
  • Ljiljana Stojković VINČA Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Department for Radiobiology and Molecular Genetics, Mike Petrovića Alasa 12-14, 11351 Belgrade, Serbia https://orcid.org/0000-0002-2245-2863
  • Ivana Kolić VINČA Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Department for Radiobiology and Molecular Genetics, Mike Petrovića Alasa 12-14, 11351 Belgrade, Serbia https://orcid.org/0000-0002-7656-5708
  • Ana Đorđević VINČA Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Department for Radiobiology and Molecular Genetics, Mike Petrovića Alasa 12-14, 11351 Belgrade, Serbia https://orcid.org/0000-0002-0316-8461
  • Evica Dinčić Military Medical Academy, Clinic for Neurology, Crnotravska 17, 11040 Belgrade, Serbia https://orcid.org/0009-0007-2945-6561
  • Aleksandra Stanković VINČA Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Department for Radiobiology and Molecular Genetics, Mike Petrovića Alasa 12-14, 11351 Belgrade, Serbia https://orcid.org/0000-0002-1050-5913
  • Maja Živković VINČA Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Department for Radiobiology and Molecular Genetics, Mike Petrovića Alasa 12-14, 11351 Belgrade, Serbia https://orcid.org/0000-0002-0447-6626

DOI:

https://doi.org/10.2298/ABS251129036S

Keywords:

multiple sclerosis, IL2RA, rs2104286, ORMDL3, IKZF3

Abstract

Paper description:

  • IL-2 affects the expression of lymphocyte function genes Ormdl3 and Ikzf3 implicated in multiple sclerosis (MS). IL2RA rs2104286, a genetic variant strongly associated with MS, affects disease risk by attenuating IL-2 signaling.
  • In 66 relapsing-remitting MS patients and 45 controls, the association of blood mononuclear cell ORMDL3 and IKZF3 mRNA expression levels with rs2104286 were tested, assessed by qPCR.
  • In the MS group, increased expression of target genes, and in controls, lower expression of IKZF3 was associated with the protective G allele.
  • A disease-specific association between rs2104286 and ORMDL3 and IKZF3 gene expression is proposed.

Abstract: The genetic variant IL2RA rs2104286 (A>G) is strongly associated with multiple sclerosis (MS) risk. It modulates IL-2 signaling, thereby influencing the expression of lymphocyte function-related genes ORMDL3 and IKZF3 that are implicated in multiple sclerosis pathogenesis. This study aimed to investigate the association of rs2104286 with ORMDL3 and IKZF3 mRNA expression in peripheral blood mononuclear cells (PBMCs) of relapsing-remitting multiple sclerosis (RRMS) patients and controls. The study included 66 RRMS patients and 45 healthy controls from the Serbian population. Genotyping and gene expression analysis were performed using qPCR. In RRMS patients, increased ORMDL3 and IKZF3 mRNA expression was associated with the MS-protective G allele (ORMDL3: P = 0.014, 1.35-fold increase; IKZF3: P = 0.023, 1.38-fold increase). In controls, decreased expression of IKZF3 was associated with the G allele (P=0.038, 0.72-fold change). Sex, disease phase, interferon β therapy, and the ORMDL3 and IKZF3 expression quantitative trait locus (rs12946510) did not influence the association between target gene expression and rs2104286. The overall results suggest a disease-specific association between the IL2RA rs2104286 variant and ORMDL3 and IKZF3 expression. Our findings support the notion that the rs2104286 variant may modulate IL-2 signaling in PBMCs, thereby influencing the expression of the immune-relevant genes ORMDL3 and IKZF3.

Downloads

Download data is not yet available.

References

Lassmann H. Multiple Sclerosis Pathology. Cold Spring Harb Perspect Med. 2018;8(3):a028936. https://doi.org/10.1101/cshperspect.a028936

O'Gorman C, Lin R, Stankovich J, Broadley SA. Modelling genetic susceptibility to multiple sclerosis with family data. Neuroepidemiology. 2013;40(1):1-12. https://doi.org/10.1159/000341902

Patsopoulos NA. Genetics of Multiple Sclerosis: An Overview and New Directions. Cold Spring Harb Perspect Med. 2018;8(7):a028951. https://doi.org/10.1101/cshperspect.a028951

International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365(6460):eaav7188. https://doi.org/10.1126/science.aav7188

International Multiple Sclerosis Genetics Consortium; Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel SB, Mirel DB, Ivinson AJ, Pericak-Vance MA, Gregory SG, Rioux JD, McCauley JL, Haines JL, Barcellos LF, Cree B, Oksenberg JR, Hauser SL. Risk alleles for multiple sclerosis identified by a genome-wide study. N Engl J Med. 2007;357(9):851-62. https://doi.org/10.1056/NEJMoa073493

Maier LM, Lowe CE, Cooper J, Downes K, Anderson DE, Severson C, Clark PM, Healy B, Walker N, Aubin C, Oksenberg JR, Hauser SL, Compston A, Sawcer S; International Multiple Sclerosis Genetics Consortium; De Jager PL, Wicker LS, Todd JA, Hafler DA. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 2009;5(1):e1000322. https://doi.org/10.1371/journal.pgen.1000322

International Multiple Sclerosis Genetics Consortium (IMSGC); Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC); Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45(11):1353-60. https://doi.org/10.1038/ng.2770

Stefanović M, Životić I, Stojković L, Dinčić E, Stanković A, Živković M. The association of genetic variants IL2RA rs2104286, IFI30 rs11554159 and IKZF3 rs12946510 with multiple sclerosis onset and severity in patients from Serbia. J Neuroimmunol. 2020;347:577346. https://doi.org/10.1016/j.jneuroim.2020.577346

Farh KK, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, Beik S, Shoresh N, Whitton H, Ryan RJ, Shishkin AA, Hatan M, Carrasco-Alfonso MJ, Mayer D, Luckey CJ, Patsopoulos NA, De Jager PL, Kuchroo VK, Epstein CB, Daly MJ, Hafler DA, Bernstein BE. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. 2015;518(7539):337-43. https://doi.org/10.1038/nature13835

Cerosaletti K, Schneider A, Schwedhelm K, Frank I, Tatum M, Wei S, Whalen E, Greenbaum C, Kita M, Buckner J, Long SA. Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients. PLoS One. 2013;8(12):e83811. https://doi.org/10.1371/journal.pone.0083811

Schwartz AM, Demin DE, Vorontsov IE, Kasyanov AS, Putlyaeva LV, Tatosyan KA, Kulakovskiy IV, Kuprash DV. Multiple single nucleotide polymorphisms in the first intron of the IL2RA gene affect transcription factor binding and enhancer activity. Gene. 2017;602:50-6. https://doi.org/10.1016/j.gene.2016.11.032

Buhelt S, Søndergaard HB, Oturai A, Ullum H, von Essen MR, Sellebjerg F. Relationship between Multiple Sclerosis-Associated IL2RA Risk Allele Variants and Circulating T Cell Phenotypes in Healthy Genotype-Selected Controls. Cells. 2019;8(6):634. https://doi.org/10.3390/cells8060634

Brusko TM, Wasserfall CH, Hulme MA, Cabrera R, Schatz D, Atkinson MA. Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation. PLoS One. 2009;4(11):e7980. https://doi.org/10.1371/journal.pone.0007980

Maier LM, Anderson DE, Severson CA, Baecher-Allan C, Healy B, Liu DV, Wittrup KD, De Jager PL, Hafler DA. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol. 2009;182(3):1541-7. https://doi.org/10.4049/jimmunol.182.3.1541

Buhelt S, Ratzer RL, Christensen JR, Börnsen L, Sellebjerg F, Søndergaard HB. Relationship between soluble CD25 and gene expression in healthy individuals and patients with multiple sclerosis. Cytokine. 2017;93:15-25. https://doi.org/10.1016/j.cyto.2017.04.024

Buhelt S, Laigaard HM, von Essen MR, Ullum H, Oturai A, Sellebjerg F, Søndergaard HB. IL2RA Methylation and Gene Expression in Relation to the Multiple Sclerosis-Associated Gene Variant rs2104286 and Soluble IL-2Rα in CD8+ T Cells. Front Immunol. 2021;12:676141. https://doi.org/10.3389/fimmu.2021.676141

Li P, Mitra S, Spolski R, Oh J, Liao W, Tang Z, Mo F, Li X, West EE, Gromer D, Lin JX, Liu C, Ruan Y, Leonard WJ. STAT5-mediated chromatin interactions in superenhancers activate IL-2 highly inducible genes: Functional dissection of the Il2ra gene locus. Proc Natl Acad Sci U S A. 2017;114(46):12111-9. https://doi.org/10.1073/pnas.1714019114

Stefanović M, Stojković L, Životić I, Dinčić E, Stanković A, Živković M. Expression levels of GSDMB and ORMDL3 are associated with relapsing-remitting multiple sclerosis and IKZF3 rs12946510 variant. Heliyon. 2024;10(3):e25033. https://doi.org/10.1016/j.heliyon.2024.e25033

Carreras-Sureda A, Cantero-Recasens G, Rubio-Moscardo F, Kiefer K, Peinelt C, Niemeyer BA, Valverde MA, Vicente R. ORMDL3 modulates store-operated calcium entry and lymphocyte activation. Hum Mol Genet. 2013;22(3):519-30. https://doi.org/10.1093/hmg/dds450

Davis DL, Gable K, Suemitsu J, Dunn TM, Wattenberg BW. The ORMDL/Orm-serine palmitoyltransferase (SPT) complex is directly regulated by ceramide: Reconstitution of SPT regulation in isolated membranes. J Biol Chem. 2019;294(13):5146-56. https://doi.org/10.1074/jbc.RA118.007291

Zheng W, Kollmeyer J, Symolon H, Momin A, Munter E, Wang E, Kelly S, Allegood JC, Liu Y, Peng Q, Ramaraju H, Sullards MC, Cabot M, Merrill AH Jr. Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim Biophys Acta. 2006;1758(12):1864-84. https://doi.org/10.1016/j.bbamem.2006.08.009

Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science. 2005;309(5741):1735-9. https://doi.org/10.1126/science.1113640

Romero F, Martínez-A C, Camonis J, Rebollo A. Aiolos transcription factor controls cell death in T cells by regulating Bcl-2 expression and its cellular localization. EMBO J. 1999;18(12):3419-30. https://doi.org/10.1093/emboj/18.12.3419

Zhuang Y, Lu Y, Li D, Sun N, Ju X. Upregulation of AIOLOS induces apoptosis and enhances etoposide chemosensitivity in Jurkat leukemia cells. Oncol Rep. 2015;33(3):1319-25. https://doi.org/10.3892/or.2014.3677

Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, Kozoriz D, Weiner HL, Quintana FJ. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol. 2010;11(9):846-53. https://doi.org/10.1038/ni.1915

Zurawska AE, Mycko MP, Selmaj I, Raine CS, Selmaj KW. Multiple Sclerosis: circRNA Profile Defined Reveals Links to B-Cell Function. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1041. https://doi.org/10.1212/NXI.0000000000001041

Schmiedel BJ, Seumois G, Samaniego-Castruita D, Cayford J, Schulten V, Chavez L, Ay F, Sette A, Peters B, Vijayanand P. 17q21 asthma-risk variants switch CTCF binding and regulate IL-2 production by T cells. Nat Commun. 2016;7:13426. https://doi.org/10.1038/ncomms13426

Gresle MM, Jordan MA, Stankovich J, Spelman T, Johnson LJ, Laverick L, Hamlett A, Smith LD, Jokubaitis VG, Baker J, Haartsen J, Taylor B, Charlesworth J, Bahlo M, Speed TP, Brown MA, Field J, Baxter AG, Butzkueven H. Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cells. Life Sci Alliance. 2020;3(7):e202000650. https://doi.org/10.26508/lsa.202000650

GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369(6509):1318-30. https://doi.org/10.1126/science.aaz1776

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302. https://doi.org/10.1002/ana.22366

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. https://doi.org/10.1016/S1474-4422(17)30470-2

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-86. https://doi.org/10.1212/WNL.0000000000000560

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-52. https://doi.org/10.1212/wnl.33.11.1444

Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005;64(7):1144-51. https://doi.org/10.1212/01.WNL.0000156155.19270.F8

Witkowska AM, Socha K, Kochanowicz J, Karpińska E, Jakoniuk M, Zujko ME, Wilkiel M, Borawska MH, Mariak Z. Serum Levels of Biomarkers of Immune Activation and Associations With Neurological Impairment in Relapsing-Remitting Multiple Sclerosis Patients During Remission. Biol Res Nurs. 2016;18(1):113-9. https://doi.org/10.1177/1099800415583105

Peerlings D, Mimpen M, Damoiseaux J. The IL-2 - IL-2 receptor pathway: Key to understanding multiple sclerosis. J Transl Autoimmun. 2021;4:100123. https://doi.org/10.1016/j.jtauto.2021.100123

Ferrarini AM, Sivieri S, Buttarello M, Facchinetti A, Perini P, Gallo P. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients. Mult Scler. 1998;4(3):174-7. https://doi.org/10.1177/135245859800400316

Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 2001;61(1):237-42.

Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Pontén F. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. https://doi.org/10.1126/science.1260419

Autissier P, Soulas C, Burdo TH, Williams KC. Evaluation of a 12-color flow cytometry panel to study lymphocyte, monocyte, and dendritic cell subsets in humans. Cytometry A. 2010;77(5):410-9. https://doi.org/10.1002/cyto.a.20859

41. Kleiveland CR. Peripheral blood mononuclear cells. In: Verhoeckx K, Cotter P, López-Expósito I, Kleiveland CR, Lea T, Mackie A, Requena T, Swiatecka D, Wichers H, editors. The Impact of Food Bioactives on Health. Cham, Switzerland: Springer; 2015. 161-7 p.

https://doi.org/10.1007/978-3-319-16104-4_15

Downloads

Published

2026-04-09

How to Cite

1.
Stefanović M, Stojković L, Kolić I, Đorđević A, Dinčić E, Stanković A, Živković M. Association of ORMDL3 and IKZF3 expression with the IL2RA rs2104286 risk variant in relapsing-remitting multiple sclerosis. Arch Biol Sci [Internet]. 2026Apr.9 [cited 2026Apr.10];78(1):33-4. Available from: https://www.serbiosoc.org.rs/arch/index.php/abs/article/view/11921

Issue

Vol. 78 No. 1 (2026)

Section

Articles

License

Copyright (c) 2025 Milan B. Stefanović, Ljiljana S. Stojković, Ivana Z. Kolić, Ana M. Đorđević, Evica R. Dinčić, Aleksandra D. Stanković, Maja D. Živković

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.

Most read articles by the same author(s)